Financial Performance - The company's revenue for Q1 2025 was ¥96,994,677.03, a decrease of 10.46% compared to ¥108,322,506.68 in the same period last year[5] - The net profit attributable to shareholders was a loss of ¥3,564,740.69, representing a decline of 272.34% from a profit of ¥2,068,381.83 in the previous year[5] - Total operating revenue decreased to ¥96,994,677.03 from ¥108,322,506.68, a decline of approximately 10.2% year-over-year[20] - Operating profit turned negative at ¥-3,734,479.32, down from a positive operating profit of ¥2,476,875.18 in the prior year[21] - Basic and diluted earnings per share were both ¥-0.03, compared to ¥0.02 in the previous period[22] - The weighted average return on net assets was -0.23%, a decrease of 0.36% compared to 0.13% in the previous year[5] Cash Flow and Assets - The net cash flow from operating activities was negative at ¥28,010,536.70, a decrease of 153.72% compared to ¥52,145,490.57 in the same period last year[5][10] - Cash inflow from sales of goods and services was 68,877,403.51, down from 131,967,300.97 in the previous period[23] - Total cash outflow from operating activities was 102,074,168.50, compared to 84,910,887.82 in the previous period, indicating an increase of approximately 20.5%[23] - The ending balance of cash and cash equivalents was 145,197,240.99, a decrease from 289,168,255.37 in the prior period[24] - The company reported a significant increase in cash and cash equivalents, with a net increase of ¥83,415,507.74, although this was a decrease of 47.35% from ¥158,434,972.87 in the previous year[10] - Cash inflow from investment activities totaled 341,887,265.55, compared to 191,461,695.62 in the prior period, marking an increase of approximately 78.7%[24] - The net cash flow from investment activities was 111,242,414.72, slightly up from 106,032,688.92 in the previous period[24] Expenses and Liabilities - Total operating costs decreased to ¥104,540,673.11 from ¥111,604,696.36, a decline of about 6.3% year-over-year[21] - The company experienced a 70.66% increase in taxes and surcharges, totaling ¥2,179,935.80, primarily due to increased VAT payments[9] - The financial expenses decreased by 80.96%, resulting in a cost of -¥138,806.37, attributed to reduced bank interest income[9] - The company reported a significant increase in management expenses to ¥23,695,005.30 from ¥20,722,760.06, reflecting a rise of about 9.5% year-over-year[21] - Total liabilities decreased to ¥202,738,401.18 from ¥205,723,871.61, a decline of approximately 1.5%[18] Shareholder Information - Total number of common shareholders at the end of the reporting period is 18,901[12] - The largest shareholder, Yang Xining, holds 27.23% of shares, totaling 34,455,650 shares[12] - The total number of restricted shares held by major shareholders remains unchanged at 35,568,187 shares[14] Assets Overview - The total assets at the end of the reporting period were ¥1,751,693,720.93, a slight decrease of 0.37% from ¥1,758,243,932.05 at the end of the previous year[5] - Non-current assets totaled ¥1,080,684,350.92, showing a marginal decrease from ¥1,081,231,768.33[18] - Total current assets amount to 671,009,370.01 RMB, a slight decrease from 677,012,163.72 RMB at the beginning of the period[16] - Inventory increased to 196,185,103.52 RMB from 178,882,618.60 RMB, reflecting a rise of 9.6%[16] - Accounts receivable rose to 89,769,097.06 RMB from 78,588,206.56 RMB, an increase of 14.2%[16] Market and Future Outlook - The company has no new product launches or technological developments reported in the current period[15] - There are no significant market expansions or mergers and acquisitions mentioned in the report[15] - The company has not provided specific future guidance or performance outlook in the current report[15]
拓新药业(301089) - 2025 Q1 - 季度财报